Suppr超能文献

人组织激肽释放酶对源自人高分子量激肽原(菲茨杰拉德因子)的促凝链的表征

Characterization of the procoagulant chain derived from human high molecular weight kininogen (Fitzgerald factor) by human tissue kallikrein.

作者信息

Maier M, Austen K F, Spragg J

出版信息

Blood. 1983 Aug;62(2):457-63.

PMID:6553501
Abstract

Human high molecular weight kininogen (HMWK), a single-chain protein with mol wt 120,000, is cleaved by human urinary kallikrein (HUK) to release kinin from within a disulfide loop and form a two-chain protein that retains all the procoagulant activity of the native molecule. Cleavage of HMWK by HUK is associated with a reduction in size to mol wt 115,000, as assessed by SDS-PAGE of unreduced protein, whereas the two chains of the reduced protein present together as a single broad band with mol wt 64,000. The 64,000 chain with procoagulant activity was chromatographically separated from the nonfunctional chain of similar size. The homogeneous procoagulant chain had an amino acid composition similar to that of smaller procoagulant ("light") chains isolated by others upon cleavage of HMWK with plasma kallikrein and elicited an antiserum that was monospecific by Ouchterlony analysis and inhibited the procoagulant function of HMWK. Thus, the limited proteolysis of HMWK by HUK has permitted, for the first time, the isolation of a stable procoagulant chain that is equal in size to the nonfunctional chain. The common terminology of "heavy" and "light" chain for kinin-free kininogen obtained with plasma kallikrein reflects the continued degradation of the procoagulant carboxyterminal chain and is not appropriate for the initial two-chain product formed when kinin is released from HMWK. It is proposed that the initial cleavage products of HMWK be designated the A-chain, the B-fragment, and the C-chain, representing the amino-terminal chain, the released vasoactive peptide containing the bradykinin sequence, and the carboxy-terminal procoagulant chain, respectively. Thus, intact HMWK would contain, in sequence, A, B, and C regions.

摘要

人高分子量激肽原(HMWK)是一种分子量为120,000的单链蛋白质,被人尿激肽释放酶(HUK)切割,从二硫键环内释放激肽,并形成一种双链蛋白质,该双链蛋白质保留了天然分子的所有促凝血活性。通过未还原蛋白质的SDS-PAGE评估,HUK对HMWK的切割伴随着分子量减小至115,000,而还原蛋白质的两条链一起呈现为一条分子量为64,000的单一宽带。具有促凝血活性的64,000链通过色谱法与大小相似的无功能链分离。均质的促凝血链的氨基酸组成与其他人用血浆激肽释放酶切割HMWK后分离出的较小促凝血(“轻”)链相似,并引发了一种抗血清,通过免疫双扩散分析该抗血清具有单特异性,且能抑制HMWK的促凝血功能。因此,HUK对HMWK的有限蛋白水解首次使得能够分离出一种大小与无功能链相等的稳定促凝血链。用血浆激肽释放酶获得的无激肽激肽原的“重”链和“轻”链的常用术语反映了促凝血羧基末端链的持续降解,不适用于从HMWK释放激肽时形成的初始双链产物。建议将HMWK的初始切割产物分别命名为A链、B片段和C链,分别代表氨基末端链、含有缓激肽序列的释放的血管活性肽和羧基末端促凝血链。因此,完整的HMWK将依次包含A、B和C区域。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验